sincerity pharmaceutical

Chengyi Pharmaceutical (603811) disclosed its 2023 annual report on April 26. In 2023, the company achieved operating income of 672 million yuan, a year-on-year increase of 2.54%; net profit attributable to the parent company was 163 million yuan, a year-on-year increase of 0.81%; non-net profit after deducting 155 million yuan, a year-on-year increase of 10.6%; net cash flow generated from operating activities was 195 million yuan, a year-on-year increase of 17.38%; during the reporting period, Chengyi Pharmaceutical’s basic earnings per share was 0.5 yuan, and the weighted average return on net assets was 14.35%. The company\’s 2023 distribution plan is: It plans to distribute 2 yuan (tax included) to all shareholders for every 10 shares.